Clinical pharmacokinetics of vancomycin in the neonate: A review

Clinics

Volumn 67, Issue 7, 2012, Pages 831-837

  Pacifici, Gian Maria ^a   Allegaert, Karel ^b  

^a UNIVERSITY OF PISA   (Italy)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Covariates; Developmental pharmacology; Neonate; Pharmacokinetics; Vancomycin

Indexed keywords

ANTIINFECTIVE AGENT; VANCOMYCIN;

AGE; DRUG MONITORING; HUMAN; KIDNEY; METABOLISM; NEWBORN; PREMATURITY; REVIEW; SEPSIS;

AGE FACTORS; ANTI-BACTERIAL AGENTS; DRUG MONITORING; HUMANS; INFANT, NEWBORN; INFANT, PREMATURE, DISEASES; KIDNEY; SEPSIS; VANCOMYCIN;

EID: 84867043003     PISSN: 18075932     EISSN: None     Source Type: Journal    
DOI: 10.6061/clinics/2012(07)21     Document Type: Review

References (56)

1. Schelonka RL, Infante AJ. Neonatal immunology. Semin Perinatol. 1998;22(1):2-14, http://dx.doi.org/10.1016/S0146-0005(98)80003-7.
2. Manzoni P, Rizzollo S, Decmebrino L, Ruffinazzi G, Rossi Ricci A, Gallo E, et al. Recent advances in prevention of sepsis in the premature neonates in NICU. Early Human Dev. 2011;87(suppl 1):S1-3, http://dx.doi.org/10.1016/j.earlhumdev.2011.01.026.
3. Black RE, Cousens S, Johnson HL, Lawn JE, Rudan I, Bassani DG, et al. Child Health Epidemiology Reference Group of WHO and UNICEF. Global, regional, and national causes of child mortality in 2008: a systematic analysis. Lancet. 2010;375(9730):1969-87, http://dx.doi.org/10.1016/S0140-6736(10)60549-1.
4. de Hoog M, Mouton JW, van den Anker JN. Vancomycin pharmacokinetics and administration regimens in neonates. Clin Pharmacokinet. 2004;43(7):417-40, http://dx.doi.org/10.2165/00003088-200443070-00001.
5. th Edition. Brunton LL Lazo JS Lazo and Parker KL eds. pp 1194-1197. McGraw-Hill, New York 2006.
6. Gabriel MH, Kildoo GC 3rd, Gennrich JL, Modanlou HD, Collins SR. Prospective evaluation of a vancomycin dosage guideline for neonates. Clin Pharm. 1991;10(2)129-32.
7. Sato Y. Pharmacokinetics of antibiotics in neonates. Acta Paediatr Jpn. 1997;39(1):124-131, http://dx.doi.org/10.1111/j.1442-200X.1997.tb03569.x.
8. rd edition, 2010, pages 96-97. Thomson Reuters, Montvale, NJ, USA.
9. Allegaert K, Verbesselt R, Naulaers G, van den Anker JN, Rayyan M, Debeer A, et al. Developmental pharmacology: neonates are not just small adults. Acta Clin Belg. 2008;63(1)16-24.
10. Grimsley C, Thomson AH. Pharmacokinetics and dose requirements of vancomycin in neonates. Arch Dis Child Fetal Neonatal Ed. 1999;81(3):F221-7.
11. Capparelli EV, Lane JR, Romanowski GL, McFeely EJ, Murray W, Sousa P, et al. The influences of renal function and maturation on vancomycin elimination in newborns and infants. J Clin Pharmacol. 2001;41(9):927-34.
12. McDougal A, Ling EW, Levine M. Vancomycin pharmacokinetics and dosing in premature neonates. Ther Drug Monit. 1995;17(4):319-26, http://dx.doi.org/10.1097/00007691-199508000-00001.
13. Reed MD, Kliegman RM, Weiner JS, Huang M, Yamashita TS, Blumer JL. The clinical pharmacology of vancomycin in seriously ill preterm infants. Pediatr Res. 1987;22(3):360-3, http://dx.doi.org/10.1203/00006450-198709000-00024.
14. Leonard MB, Koren G, Stevenson DK, Prober CG. Vancomycin pharmacokinetics in very low birth weight neonates. Pediatr Infect Dis J. 1989;8(5):282-6.
15. Machado JK, Feferbaum R, Kobayashi CE, Sanches C, Santos SR. Vancomycin pharmacokinetics in preterm infants. Clinics. 2007;62(4):405-10, http://dx.doi.org/10.1590/S1807-59322007000400006.
16. James A, Koren G, Milliken J, Soldin S, Prober C. Vancomycin pharmacokinetics and dose recommendations for preterm infants. Antimicrob Agents Chemother. 1987;31(1):52-4.
17. Frattarelli DA, Ergun H, Lulic-Botica M, Lehr VT, Aranda JV. Vancomycin elimination in human infants with intrauterine growth retardation. Pediatr Infect Dis J. 2005;24(11):979-83.
18. Kildoo CW, Lin LM, Gabriel MH, Folli HL, Modanlou HD. Vancomycin pharmacokinetics in infants: relationship to postconceptional age and serum creatinine. Dev Pharmacol Ther. 1990;14(2):77-83.
19. Lo YL, van Hasselt JG, Heng SC, Lim CT, Lee TC, Charles BG. Population pharmacokinetics of vancomycin in premature Malaysian neonates: identification of predictors for dosing determination. Antimicrob Agents Chemother. 2010;54(6):2626-32, http://dx.doi.org/10.1128/AAC.01370-09.
20. de Hoog M, Schoemaker RC, Mouton JW, van den Anker JN. Vancomycin population pharmacokinetics in neonates. Clin Pharmacol Ther 2000;67(4):360-7, http://dx.doi.org/10.1067/mcp.2000.105353.
21. Seay RE, Brundage RC, Jensen PD, Schilling CG, Edgren BE. Population pharmacokinetics of vancomycin in neonates. Clin Pharmacol Ther. 1994;56(2):169-75, http://dx.doi.org/10.1038/clpt.1994.120.
22. Marqués-Miñana MR, Saadeddin A, Peris JE. Population pharmacokinetic analysis of vancomycin in neonates. A new proposal of initial dosage guideline. Br J Clin Pharmacol. 2010;70(5):713-20.
23. Jarrett RV, Marinkovich GA, Gayle EL, Bass JW. Individualized pharmacokinetic profiles to compute vancomycin dosage and dosing interval in preterm infants. Pediatr Infect Dis J. 1993;12(2):156-7.
24. Buck ML. Vancomycin pharmacokinetics in neonates receiving extracorporeal membrane oxygenation. Pharmacotherapy. 1998;18(5):1082-6.
25. Amaker RD, DiPiro JT, Bhatia J. Pharmacokinetics of vancomycin in critically ill infants undergoing extracorporeal membrane oxygenation. Antimicrob Agents Chemother. 1996;40(5):1139-42.
26. Asbury WH, Darsey EH, Rose WB, Murphy JE, Buffington DE, Capers CC. Vancomycin pharmacokinetics in neonates and infants: a retrospective evaluation. Ann Pharmacother. 1993;27(4):490-6.
27. Schaad UB, McCracken GH Jr, Nelson JD. Clinical pharmacology and efficacy of vancomycin in pediatric patients. J Pediatr. 1980;96(1):119-26.
28. Anderson BJ, Allegaert K, Van den Anker JN, Cossey V, Holford NH. Vancomycin pharmacokinetics in preterm neonates and the prediction of adult clearance. Br J Clin Pharmacol. 2006;63(1):75-84.
29. Allegaert K, Anderson BJ, van den Anker JN, Vanhaesebrouck S, de Zegher F. Renal drug clearance in preterm neonates: relation to prenatal growth. Ther Drug Monit. 2007;29(3):284-91, http://dx.doi.org/10.1097/FTD.0b013e31806db3f5.
30. Silva R, Reis E, Bispo MA, Almeida AM, Costa IM, Falcão F, et al. The kinetic profile of vancomycin in neonates. J Pharm Pharmacol. 1998;50(11):1255-60, http://dx.doi.org/10.1111/j.2042-7158.1998.tb03342.x.
31. Allegaert K. The impact of ibuprofen or indomethacin on renal drug clearance in neonates. J Matern Fetal Neonatal Med. 2009;22(Suppl 3):88-91, http://dx.doi.org/10.1080/14767050903180965.
32. Reiter PD, Doron MW. Vancomycin cerebrospinal fluid concentrations after intravenous administration in premature infants. J Perinatol. 1996;16(5):331-5.
33. Pau AK, Smego RA Jr, Fisher MA. Intraventricular vancomycin: observations of tolerance and pharmacokinetics in two infants with ventricular shunt infections. Pediatr Infect Dis. 1986;5(1):93-6.
34. Dawson PM. Vancomycin and gentamicin in neonates: hindsight, current controversies, and forethought. J Perinat Neonatal Nurs. 2002;16(2):54-72.
35. Isaacs D. Rationing antibiotic use in neonatal units. Arch Dis Child Fetal Neonatal Ed. 2000;82(1):F1-2, http://dx.doi.org/10.1136/fn.82.1.F1.
36. Moise-Broder PA, Forrest A, Birmingham MC, Schentag JJ. Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections. Clin Pharmacokinet. 2004;43(13):925-42, http://dx.doi.org/10.2165/00003088-200443130-00005.
37. Frymoyer A, Hersh AL, Benet LZ, Guglielmo BJ. Current recommended dosing of vancomycin for children with invasive methicillin-resistant Staphylococcus aureus infections is inadequate. Pediatr Infect Dis J. 2009;28(5):398-402.
38. Lutsar I, Metsvaht T. Understanding pharmacokinetics/pharmacodynamics in managing neonatal sepsis. Curr Opin Infect Dis. 2010;23(3):201-7, http://dx.doi.org/10.1097/QCO.0b013e328337bb42.
39. van den Anker JN. Getting the dose of vancomycin right in the neonate. Int J Clin Pharmacol Ther. 2011;49(4):247-9.
40. Center KJ, Reboli AC, Hubler R, Rodgers GL, Long SS. Decreased vancomycin susceptibility of coagulase-negative staphylococci in a neonatal intensive care unit: evidence of spread of Staphylococcus warneri. J Clin Microbiol. 2003;41(10):4660-5, http://dx.doi.org/10.1128/JCM.41.10.4660-4665.2003.
41. Badran EF, Shamayleh A, Irshaid YM. Pharmacokinetics of vancomycin in neonates admitted to the neonatology unit at the Jordan University Hospital. Int J Clin Pharmacol Ther. 2011;49(4):252-7.
42. Plan O, Cambonie G, Barbotte E, Meyer P, Devine C, Milesi C, et al. Continuous-infusion vancomycin therapy for preterm neonates with suspected or documented Gram-positive infections: a new dosage schedule. Arch Dis Child Fetal Neonatal Ed. 2008;93(6):F418-21, http://dx.doi.org/10.1136/adc.2007.128280.
43. Pawlotsky F, Thomas A, Kergueris MF, Debillon T, Roze JC. Constant rate infusion of vancomycin in premature neonates: a new dosage schedule. Br J Clin Pharmacol. 1998;46(2):163-7.
44. Oudin C, Vialet R, Boulamery A, Martin C, Simon N. Vancomycin prescription in neonates and young infants: towards a simplified dosage. Arch Dis Child Fetal Neonatal Ed. 2011;96(5):F365-70, http://dx.doi.org/10.1136/adc.2010.196402.
45. Embleton ND, Berrington J. Giving vancomycin as a continuous infusion. Arch Dis Child Fetal Neonatal Ed. 2009;94(3):F233-4.
46. Fanos V, Cuzzolin L, Atzei A, Testa M. Antibiotics and antifungals in neonatal intensive care units: a review. J Chemother. 2007;19(1):5-20.
47. Goetz MB, Sayers J. Nephrotoxicity of vancomycin and aminoglycoside therapy separately and in combination. J Antimicrob Chemother. 1993;32(2):325-34, http://dx.doi.org/10.1093/jac/32.2.325.
48. Rybak MJ, Albrecht LM, Boike SC, Chandrasekar PH. Nephrotoxicity of vancomycin, alone and with an aminoglycoside. J Antimicrob Chemother. 1990;25(4):679-87, http://dx.doi.org/10.1093/jac/25.4.679.
49. Rodvold KA, Everett JA, Pryka RD, Kraus DM. Pharmacokinetics and administration regimens of vancomycin in neonates, infants and children. Clin Pharmacokinet. 1997;33(1):32-51, http://dx.doi.org/10.2165/00003088-199733010-00004.
50. Nahata MC. Lack of nephrotoxicity in pediatric patients receiving concurrent vancomycin and aminoglycoside therapy. Chemotherapy. 1987;33(4):302-4, http://dx.doi.org/10.1159/000238512.
51. Goren MP, Baker DK Jr, Shenep JL. Vancomycin does not enhance amikacin-induced tubular nephrotoxicity in children. Pediatr Infect Dis J. 1989;8(5):278-82.
52. Duffull SB, Begg EJ. Vancomycin toxicity. What is the evidence for dose dependency? Adverse Drug React Toxicol Rev. 1994;13(2):103-14.
53. Iwamoto T, Kagawa Y, Kojima M. Factors influencing the overestimation of plasma vancomycin concentrations measured by the Abbott TDx technique. Ther Drug Monit. 2005;27(1):58-62, http://dx.doi.org/10.1097/00007691-200502000-00012.
54. George I, Mekahli D, Rayyan M, Levtchenko E, Allegaert K. Postnatal trends in creatinemia and its covariates in extremely low birth weight (ELBW) neonates. Pediatr Nephrol. 2011;26(10):1843-9, http://dx.doi.org/10.1007/s00467-011-1883-0.
55. Kuppens M, George I, Lewi L, Levtchenko E, Allegaert K. Creatinaemia at birth is equal to maternal creatinaemia at delivery: does this paradigm still hold? J Matern Fetal Neonatal Med. 2011; Aug 25, http://dx.doi. org/10.3109/14767058.2011.602144.
56. Mulla H, Pooboni S. Population pharmacokinetics of vancomycin in patients receiving extracorporeal membrane oxygenation. Br J Clin Pharmacol. 2005;60(3):265-75, http://dx.doi.org/10.1111/j.1365-2125.2005.02432.x.